

**SCHEDULE 14A INFORMATION**

**Proxy Statement Pursuant to Section 14(a) of the  
Securities Exchange Act of 1934 (Amendment No. )**

Filed by the Registrant

Filed by a Party other than the Registrant

Check the appropriate box:

- Preliminary Proxy Statement
- Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
- Definitive Proxy Statement
- Definitive Additional Materials
- Soliciting Material under §240.14a-12

**NAVIDEA BIOPHARMACEUTICALS, INC.**  
(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):

- No fee required.
  - Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11
    - (1) Title of each class of securities to which transaction applies:
    - (2) Aggregate number of securities to which transaction applies:
    - (3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (Set forth the amount on which the filing fee is calculated and state how it was determined):
    - (4) Proposed maximum aggregate value of transaction:
    - (5) Total fee paid:
  - Fee paid previously with preliminary materials.
  - Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.
    - (1) Amount Previously Paid:
    - (2) Form, Schedule or Registration Statement No.:
    - (3) Filing Party:
    - (4) Date Filed:
-



5600 Blazer Parkway  
Suite 200  
Dublin, OH 43017-7550

phone 614.793.7500  
fax 614.793.7522  
www.navidea.com

July 6, 2015

Dear Navidea Stockholder:

I am writing to advise you that due to personal reasons, Peter F. Drake, Ph.D., a Navidea director and nominee for re-election as a director at our 2015 Annual Meeting of Stockholders to be held on July 16, 2015, has advised Navidea that he has decided not to stand for re-election at the Annual Meeting. As a consequence, Gordon A. Troup will be the only nominee standing for election as a director of Navidea at the 2015 Annual Meeting.

There is no need for you to take any additional action with respect to returning a proxy or voting your shares. If you have already returned a proxy card marked for the election of all nominees (or if you have voted for all electronically), your vote will not be counted for Dr. Drake. If you have not yet returned your proxy card or voted electronically, you may mark your proxy card or vote electronically to vote for all nominees, and no vote will be recorded for Dr. Drake. If you mark or have marked your proxy to withhold authority with respect to the election of all nominees, or with respect to Dr. Drake individually, no vote will be recorded for Dr. Drake.

Navidea wishes to thank Dr. Drake for his four years of service as a Navidea director, and for his many contributions and wise counsel during his service.

The Compensation, Nominating and Governance Committee of Navidea's Board of Directors has commenced the process of identifying one or more director candidates who will complement the Company's ongoing evolution to unlock the full value of its Manoccept<sup>®</sup> platform in both diagnostic and therapeutic applications.

Thank you for your continued support.

Very truly yours,

/s/ Ricardo J. Gonzalez

Ricardo J. Gonzalez  
Director, President and Chief Executive Officer

---